The investment seeks to replicate as closely as possible, before fees and expenses, the price and yield performance of the Market Vectors? US Listed Biotech 25 Index. The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The Biotech Index is comprised of common stocks and depositary receipts of U.S. exchange-listed companies in the biotechnology sector. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Inception Date: 20/12/2011
Primary Benchmark: MVIS US Listed Biotech 25 NR USD
Primary Index: MSCI ACWI NR USD
Gross Expense Ratio: 0.4%
Management Expense Ratio: 0.35 %
|AMGN||Amgen Inc.||8.94 %|
|GILD||Gilead Sciences Inc.||7.08 %|
|VRTX||Vertex Pharmaceuticals Incorporated||5.35 %|
|BIIB||Biogen Inc.||5.18 %|
|ILMN||Illumina Inc.||5.09 %|
|REGN||Regeneron Pharmaceuticals Inc.||4.96 %|
|ALXN||Alexion Pharmaceuticals Inc.||4.95 %|
|IQV||IQVIA Holdings Inc.||4.75 %|
|EXAS||Exact Sciences Corporation||4.65 %|
|IBB||iShares Nasdaq Biotechnology I..||0.47 %||
|PSCH||Invesco S&P SmallCap Health Ca..||0.29 %||
|PPH||VanEck Vectors Pharmaceutical ..||0.35 %||
|PTH||Invesco DWA Healthcare Momentu..||0.60 %||
|BTEC||Principal Healthcare Innovator..||0.42 %||
|CNCR||Loncar Cancer Immunotherapy ET..||0.79 %||
|FTXH||First Trust Nasdaq Pharmaceuti..||0.60 %||
|GNRX||VanEck Vectors Generic Drugs E..||0.57 %||
|SLIM||The Obesity ETF||0.50 %||
|LNGR||Global X Longevity Thematic ET..||0.52 %||
|Market Performance vs.
|Market Performance vs. Exchange (NASDAQ Global Market)|
|Value||Sector Median||Percentile Rank||Grade||Market Median||Percentile Rank||Grade|
|Trailing 12 Months|
|Trailing 5 Years|
|Average Annual (5 Year Horizon)|
|Risk Return Profile|
|Volatility (Standard Deviation)||19.48%||27%||F||64%||D|
|Risk Adjusted Return||41.12%||36%||F||53%||F|
|Target Price Action||Rating Action||Analyst||Rating||Price||Date|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.
The company has under performed its peers on annual average total returns in the past 5 years.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.